Story perspectives

Senators Demand Halt on Mifepristone Approvals Amid Safety Concerns

11/5/2025

Summary

Story summary

U.S. Senator Dave McCormick and 51 Republican senators requested the FDA to stop new approvals for mifepristone in a letter dated October 10, citing health risks and insufficient oversight.
They called for a comprehensive safety review, highlighting a 20% increase in emergency room visits and a 15% rise in postpartum depression associated with the drug.
In Pennsylvania, medication-induced abortions represented 56% of over 35,000 procedures in 2023, prompting the senators to advocate for in-person consultations and mandatory ultrasounds to mitigate complications.

History

Historical Context

Mifepristone, approved by the FDA in September 2000, revolutionized abortion access in the U.S., with medication abortions rising to 63% of all procedures by 2023. Following the 2022 Supreme Court decision in Dobbs v. Jackson, which overturned Roe v. Wade, states have enacted stricter regulations, intensifying the debate over reproductive rights and healthcare access amid rising emergency room visits linked to the drug.

1 of 2

Story summary

U.S. Senator Dave McCormick and 51 Republican senators requested the FDA to stop new approvals for mifepristone in a letter dated October 10, citing health risks and insufficient oversight.
They called for a comprehensive safety review, highlighting a 20% increase in emergency room visits and a 15% rise in postpartum depression associated with the drug.
In Pennsylvania, medication-induced abortions represented 56% of over 35,000 procedures in 2023, prompting the senators to advocate for in-person consultations and mandatory ultrasounds to mitigate complications.

1 / 2